Group 1 - AP Biosciences has finalized an amendment to its collaboration with Tasly Pharmaceutical Group, establishing a framework for the out-licensing of AP505 (B1962) outside the original agreement's designated territory [1][2] - AP505 (B1962) has completed a Phase 1 clinical study and is currently in Phase 2 trials for advanced solid tumors, indicating its potential for further development [2] - The amended agreement enhances the collaboration by allowing Tasly to support AP Biosciences' global development efforts through clinical data sharing and regulatory materials on a revenue-sharing basis [3] Group 2 - AP505 (B1962) is a bispecific antibody designed to target PD-L1 and VEGF, aiming to improve anti-tumor activity by addressing immune suppression and tumor-driven angiogenesis [4] - AP Biosciences is a clinical-stage biopharmaceutical company focused on developing innovative antibody-based therapies for cancer, utilizing proprietary platforms for bispecific antibodies [5]